Top View
- INN Working Document 05.179 Update 2011
- A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
- Inflammatory Conditions – Ilaris® (Canakinumab for Subcutaneous Injection)
- Pipeline: Respiratory, Inflammation & Autoimmunity (RIA) Inhaled Therapeutic Leadership; Spearheading Immunology Biologics
- (INN) for Biological and Biotechnological Substances
- Drug Therapy Advancements in Specialty Pharmacy Michael Mccall, Pharm.D
- Kevzara (Sarilumab)
- Siliq™ (Brodalumab for Subcutaneous Injection)
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- RIA TA Strategy 2013
- 2017 Annual Review & Extract from Annual Report
- AZ Enters Licensing Agreements with LEO Pharma
- Targeted Immunomodulators for Plaque Psoriasis: Effectiveness and Value Condition Update Public Meeting – Morning Session July 12, 2018
- Defining the Role of Interleukin 17 in Rheumatoid Arthritis
- Emerging Therapeutic Options for the Treatment of Patients with Symptomatic Asthma R
- 1 Brodalumab in Psoriatic Arthritis: Results from the Randomised Phase
- Monoclonal Antibodies in Asthma
- Utah Medicaid Pharmacy and Therapeutics Committee Drug
- Brodalumab (Siliq)
- Utah Medicaid Dur Report February 2019 Brodalumab
- Az Immunfarmakológia Alapjai És Immuntoxikológia
- Policy: 201703 Initial Effective Date: 02/14/2017 HCPCS J0638 Code(S): Annual Review Date: 10/15/2020
- New Systemic Therapies for Psoriasis
- FDA Presentations for the July 19, 2016 Meeting of the Dermatologic
- Biologics for Psoriasis: a Status Update
- Certolizumab Pegol for Treating Moderate to Severe Plaque Psoriasis
- Roskos EBF Talk Sep 2018 FINAL
- Spotlight on Brodalumab in the Treatment of Moderate-To-Severe Plaque Psoriasis: Design, Development, and Potential Place in Therapy
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Brodalumab (Siliq) Reference Number: ERX.SPA.53 Effective Date: 06.01.17 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
- Treating a Co-Existence of Hidradenitis Suppurativa and Psoriasis with Different Therapeutic Approaches [Version 2; Peer Review: 3 Approved]
- 59028 Siliq Brodalumab.Pdf
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- From Messengers to Receptors in Psoriasis: the Role of IL-17RA in Disease and Treatment
- Cytokine and CAM Antagonists And
- (INN) for Biological and Biotechnological Substances
- 761067Orig1s000
- Siliq (Brodalumab)
- Risk for Deep Fungal Infections During IL-17 and IL-23 Inhibitor Therapy for Psoriasis
- Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
- NICE TA574: Certolizumab Pegol for Treating Moderate to Severe Plaque
- A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-To-Severe Plaque Psoriasis
- SILIQ (Brodalumab) RATIONALE for INCLUSION in PA PROGRAM
- PM147 Cytokine, TNF Inhibitors, & CAM Antagonists
- Kyntheum, INN-Brodalumab
- Immune Modulating Therapies for Rheumatologic, Dermatologic and Gastrointestinal Diseases
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
- Spotlight on Brodalumab in the Treatment of Moderate-To-Severe Plaque Psoriasis: Design, Development, and Potential Place in Therapy
- 761032Orig1s000
- A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 In
- Monoklonális Antitestekkel Végzett Terápiát, E) a Nagyadagú IVIG Kezelést F) Az Őssejt Kezelést, G) a Génterápiát
- Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: 06.01.18 Last Review Date: 05.21 Line of Business: Medicaid Revision Log
- Cytokine and CAM Antagonists
- Risk of Infection Associated with Biological Agents Used for Autoimmune Inflammatory Diseases
- Quantify RA Clinical Outcomes Database
- Antibodies to Watch in 2018